Charles Schwab Investment Management Inc. Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Charles Schwab Investment Management Inc. raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 695,799 shares of the biopharmaceutical company’s stock after buying an additional 22,538 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.63% of Regeneron Pharmaceuticals worth $495,639,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Howe & Rusling Inc. grew its stake in Regeneron Pharmaceuticals by 3.4% in the third quarter. Howe & Rusling Inc. now owns 462 shares of the biopharmaceutical company’s stock worth $486,000 after purchasing an additional 15 shares in the last quarter. Willner & Heller LLC increased its stake in shares of Regeneron Pharmaceuticals by 3.9% during the fourth quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company’s stock valued at $284,000 after buying an additional 15 shares during the period. OLD Second National Bank of Aurora increased its stake in shares of Regeneron Pharmaceuticals by 0.5% during the fourth quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company’s stock valued at $2,025,000 after buying an additional 15 shares during the period. Sigma Planning Corp increased its stake in shares of Regeneron Pharmaceuticals by 4.1% during the third quarter. Sigma Planning Corp now owns 409 shares of the biopharmaceutical company’s stock valued at $430,000 after buying an additional 16 shares during the period. Finally, GLOBALT Investments LLC GA increased its stake in shares of Regeneron Pharmaceuticals by 1.5% during the third quarter. GLOBALT Investments LLC GA now owns 1,067 shares of the biopharmaceutical company’s stock valued at $1,122,000 after buying an additional 16 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

REGN has been the subject of several recent research reports. UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. TD Cowen lowered their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a report on Tuesday, February 4th. Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. Wells Fargo & Company dropped their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. Finally, Truist Financial dropped their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Stock Down 1.4 %

NASDAQ:REGN opened at $675.49 on Wednesday. The firm has a market capitalization of $73.85 billion, a P/E ratio of 17.65, a PEG ratio of 2.34 and a beta of 0.08. The company’s fifty day moving average price is $697.13 and its 200-day moving average price is $859.13. Regeneron Pharmaceuticals, Inc. has a 1-year low of $642.00 and a 1-year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the firm earned $11.86 EPS. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.52%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is presently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.